SCHEMBL2092841

SCHEMBL2092841

CN(C=O)c1ccccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.36
TAAR1 Q96RJ0 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
NFE2L2 Q16236 1/20 0.34
ESR1 P03372 1/20 0.34
ALDH1A1 P00352 4/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GAA P10253 2/20 0.33
MAPT P10636 2/20 0.33
AOC3 Q16853 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 2/20 0.32
ERN1 O75460 1/20 0.32
CES2 O00748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2093581 0.83 TDP1 (0.37) TDP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL2093022 0.82 HSD17B1 (0.39) ACHETDP1ESR1ALDH1A1SMN1; SMN2
SCHEMBL2093826 0.76 ALDH1A1 (0.43) ACHEALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL2093944 0.76 TDP1 (0.40) ACHETAAR1TDP1NFE2L2ALDH1A1
SCHEMBL2094180 0.75 DDB1 (0.42) TDP1DDB1CRBNNFE2L2ALDH1A1
SCHEMBL27930560 0.75 ACHE (0.40) ACHETAAR1TDP1DDB1CRBN
SCHEMBL9462171 0.74 MAPT (0.33) TDP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL2697490 0.74 MAPT (0.33) TDP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL2090253 0.74 C1R (0.37) TDP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL2697491 0.74 CHEK1 (0.41) TDP1ALDH1A1SMN1; SMN2GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111662185-B Synthesis method of N-methyl o-fluoroaniline 江苏富鼎化学有限公司 2023-05-05 CN claimed
CN-113429297-A Method for synthesizing N-methyl o-fluoroaniline by one-pot method 江西汇和化工有限公司 2021-09-24 CN claimed
CN-111662185-A Synthesis method of N-methyl o-fluoroaniline 江苏富鼎化学有限公司 2020-09-15 CN claimed
CN-115197072-B Preparation method of N-alkyl-2-fluoroaniline 合肥星宇化学有限责任公司 2024-05-03 CN disclosed
CN-115160151-B Preparation method of N-alkyl-2-fluoroaniline 合肥星宇化学有限责任公司 2024-01-09 CN disclosed
CN-116574011-A Synthesis method of N-monomethylated aromatic amine derivative 东南大学 2023-08-11 CN disclosed
CN-111662185-B Synthesis method of N-methyl o-fluoroaniline 江苏富鼎化学有限公司 2023-05-05 CN disclosed
CN-111662185-B Synthesis method of N-methyl o-fluoroaniline 江苏富鼎化学有限公司 2023-05-05 CN disclosed
CN-115197072-A Preparation method of N-alkyl-2-fluoroaniline 合肥星宇化学有限责任公司 2022-10-18 CN disclosed
CN-115160151-A Preparation method of N-alkyl-2-fluoroaniline 合肥星宇化学有限责任公司 2022-10-11 CN disclosed
CN-113429297-A Method for synthesizing N-methyl o-fluoroaniline by one-pot method 江西汇和化工有限公司 2021-09-24 CN disclosed
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ACHE 4670/4885TAAR1 364/4885TDP1 4666/4885
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ACHE 4734/4885TAAR1 163/4885TDP1 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.